Verteporfin (Specialist drug)

How it works

After intravenous administration it accumulates in abnormal neovascular tissue; subsequent activation by a non-thermal laser of specific wavelength generates reactive oxygen species that occlude the targeted vessels.

Prescribing in practice

• Patients become transiently photosensitive and must avoid exposure of skin and eyes to bright light and direct sunlight for the period stated in the SPC to prevent severe phototoxic reactions.
• It is administered by intravenous infusion followed by timed laser activation under specialist ophthalmology supervision.
• Extravasation should be avoided as it can cause local tissue damage, and infusion site reactions can occur.

Monitoring

Monitor the infusion site for extravasation, assess visual outcomes at follow-up, and reinforce strict light-avoidance precautions during the photosensitive period.

Counselling the patient

• Avoid direct sunlight and bright indoor lights for the period your team specifies, as your skin and eyes will be very sensitive.
• If you must go outside, cover exposed skin and wear dark sunglasses; ordinary sunscreen does not protect against this reaction.
• Report any infusion-site pain or skin reactions to your team.

Evidence & guidelines

Photodynamic therapy with verteporfin for neovascular AMD was established by the TAP study and remains a recognised specialist option in selected cases.